SEARCH

SEARCH BY CITATION

References

  • 1
    Wainwright JJ, Kappus DM, McBride MA, Taranto SE, Thomas CP. Living kidney donor deaths within 2 years of donation. Am J Transplant 2012; 12(Suppl 3): 98.
  • 2
    Saunders MR, Thistlethwaite JR, Ross LF. Race and age disparities among living kidney donors who have developed End-Stage Renal Disease (ESRD) after donation. Am J Transplant 2012; 12(Suppl 3): 385.
  • 3
    Boyarsky J, Van Arendonk K, Deshpande NA, James NT, Montgomery RA, Segev DL. Difficulty obtaining insurance after liver kidney donation. Am J Transplant 2012; 12(Suppl 3): 47.
  • 4
    Reese P, Bloom R, Shults J, et al. Waiting list functional status is a potent predictor of mortality among adult kidney transplant recipients, regardless of age. Am J Transplant 2012; 12(Suppl 3): 68.
  • 5
    Singh SK, Kim J. Does expanded criteria donor status modify the outcome of kidney transplantation from donors after cardiac death? Am J Transplant 2012; 12(Suppl 3): 176.
  • 6
    Leventhal J, Abecassis M, Miller J, et al. A phase 2 clinical trial of donor specific tolerance induction in recipients of HLA disparate living donor kidney allografts by donor stem cell infusion. Am J Transplant 2012; 12(Suppl 3): 27.
  • 7
    Farney A, Rogers J, Hart L, et al. Long-term results of a prospective randomized study of alemtuzumab vs. rabbit anti-thymocyte globulin induction in kidney and kidney pancreas transplantation. Am J Transplant 2012; 12(Suppl 3): 56.
  • 8
    Schmidt N, Pharm D 1, Shields AR, et al. Randomized controlled trial of B-cell targeted induction therapy in HLA sensitized kidney transplant recipients: Preliminary results. Am J Transplant 2012; 12(Suppl 3): 56.
  • 9
    Amrouche L, Loupy A, Suberbielle C, Anglicheau D, Legendre C. Post-transplant desensitization with IVIg/anti-CD29/plasmapheresis in DSA+kidney recipients decreases CAMR incidence. Am J Transplant 2012; 12(Suppl 3): 151.
  • 10
    Halldorson J, Dodge J, Roberts JP. The impact of inter-center competition on liver transplant practices and outcomes. Am J Transplant 2012; 12(Suppl 3): 127.
  • 11
    L. Teperman, Elad Clinical Developmental Team. A phase 2b study of safety & efficacy in subjects with acute-on-chronic hepatitis or acute decompensation of cirrhosis & the use of a support system (ELAD) a human cell-based biological liver. Am J Transplant 2012; 12(Suppl 3): 64
  • 12
    Hessheimer AJ, Fondevila C, Maathuis MHJ, et al. Hypothermic oxygenated perfusion improves hepatocellular but causes Kupffer and endothelial cell injury in porcine DCD liver transplant. Am J Transplant 2012; 12(Suppl 3): 344.
  • 13
    Guarrera JV, Henry S, Bae C, et al. Machine perfusion rescue of orphan extended criteria liver allografts results in excellent outcomes. Am J Transplant 2012; 12(Suppl 3): 131.
  • 14
    O'Leary JG, Kaneku H, Susskind BM, Jennings LW, Klintmalm GB, Terasaki PL. High MFI de novo MHC class II donor specific antibody formation impairs patient survival after liver transplantation. Am J Transplant 2012; 12(Suppl 3): 68.
  • 15
    Hotta R, Ishiyama K, Ohira M, et al. Adoptive immunotherapy with donor derived-liver natural killer cells prevents HCC recurrence after liver transplantation in recipients exceeding the Milan Criteria. Am J Transplant 2012; 12(Suppl 3): 161.
  • 16
    Burton JR, Everson GT. Initial experience with telaprevir for treating hepatitis C virus in liver recipients: Virologic response, tolerability, and safety. Am J Transplant 2012; 12(Suppl 3): 188.
  • 17
    Fung J, Nevens F, DeCarlis L, et al. Everolimus with early reduction or elimination of tacrolimus in 719 de novo liver transplant recipients—12 month efficacy and safety results from H2304 study. Am J Transplant 2012; 12(Suppl 3): 28.
  • 18
    Kobashiagawa J, Pauly D, Kfoury A, et al. Effect of everolimus based immunosuppression on de novo heart transplant recipients—24 months efficacy and safety results from A2310 study. Am J Transplant 2012; 12(Suppl 3): 67.
  • 19
    CITR Investigators. 2011 Update from the Collaborative Islet Transplant Registry. Am J Transplant 2012; 12(Suppl 3): 161.
  • 20
    Horton P, Schnitzler MA, Dzebisashvili N, et al. High pre-transplant insulin requirements correlates with pancreas failure risk in SPK. Am J Transplant 2012; 12(Suppl 3): 115.
  • 21
    Schold JD, Buccini LD, Kattan MW, et al. Community health indicators are significantly associated with outcomes for kidney transplant recipients in the United States. Am J Transplant 2012; 12(Suppl 3): 45.
  • 22
    Olthoff KM, Stock PG, Liu J, et al. High MELD/PELD versus status 1AAA: Who lives, who dies, and when? Am J Transplant 2012; 12(Suppl 3): 131.
  • 23
    Theodoropoulos N, Nowicki M, Chinchilla-Reyes C, et al. Discordant serology and nucleic acid testing (NAT) results for HIV, HBV and HCV in 2010. Am J Transplant 2012; 12(Suppl 3): 28.
  • 24
    Blumberg E, Hasz R, Reese P, et al. Proceeding to donation and transplantation with apparent false positive HIV NAT testing: Initial results. Am J Transplant 2012; 12(Suppl 3): 142.
  • 25
    Limaye A, Jauser I, Loveless M, et al. Factors associated with the development of CMV viremia in high-risk (D+/R-) renal transplant patients on valganciclovir prophylaxis. Am J Transplant 2012; 12(Suppl 3): 69.
  • 26
    Sood P, Senanayeke S, Sujeet K, Johnson CP, Hariharan S. Natural history of significant and non-significant BK viremia post renal transplant. Am J Transplant 2012; 12(Suppl 3): 350.
  • 27
    Vu D, Shah T, Haraghi R, Hutchinson C, Hutchinson I, Min D. The impact of intravenous immunoglobulin treatment for BK virus nephropathy. Am J Transplant 2012; 12(Suppl 3): 350.
  • 28
    Kumar D, Cordero E, Blumberg E, et al. A prospective multicenter study of seasonal influenza infection in transplant recipients. Am J Transplant 2012; 12(Suppl 3): 117.